InfuSystem (INFU) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 11, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	INFU
Entity Registrant Name	InfuSystem Holdings, Inc
Entity Central Index Key	1,337,013
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,755,705

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 194	$ 3,398
Accounts receivable, less allowance for doubtful accounts of $5,928 and $4,989 at March 31, 2017 and December 31, 2016, respectively	12,079	11,581
Inventory	2,135	2,166
Other current assets	1,304	949
Deferred income taxes	0	2,675
Total Current Assets	15,712	20,769
Medical equipment held for sale or rental	1,371	1,642
Medical equipment in rental service, net of accumulated depreciation	26,896	28,036
Property & equipment, net of accumulated depreciation	1,914	1,997
Intangible assets, net	29,633	31,239
Deferred income taxes	16,196	12,436
Other assets	171	225
Total Assets	91,893	96,344
Current Liabilities:
Accounts payable	4,902	5,315
Capital Leases	2,715	2,938
Current portion of long-term debt	30,369	5,314
Other current liabilities	2,127	2,872
Total Current Liabilities	40,113	16,439
Long-term debt, net of current portion		26,577
Capital Leases	2,122	2,573
Other long-term liabilities	24	66
Total Long-Term Liabilities	2,146	29,216
Total Liabilities	42,259	45,655
Stockholders' Equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued	0
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,885,824 and 22,688,164, respectively, as of March 31, 2017 and 22,867,335 and 22,669,675, respectively, as of December 31, 2016	2	2
Additional paid-in capital	92,036	91,829
Retained deficit	(42,404)	(41,142)
Total Stockholders' Equity	49,634	50,689
Total Liabilities and Stockholders' Equity	$ 91,893	$ 96,344

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 5,928	$ 4,989
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,885,824	22,867,335
Common stock, shares outstanding	22,688,164	22,669,675

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net revenues:
Rentals	$ 15,137	$ 16,488
Product Sales	2,517	1,806
Net revenues	17,654	18,294
Cost of revenues:
Cost of revenues - Product, service and supply costs	4,536	3,506
Cost of revenues - Pump depreciation and disposals	2,469	2,231
Gross profit	10,649	12,557
Selling, general and administrative expenses:
Provision for doubtful accounts	1,856	1,747
Amortization of intangibles	1,411	912
Selling and marketing	2,886	2,815
General and administrative	6,465	6,669
Total selling, general and administrative	12,618	12,143
Operating (loss) income	(1,969)	414
Other (expense) income:
Interest expense	(328)	(305)
Loss on extinguishment of long term debt	0
Other (expense) income	(37)	20
Total other expense	(365)	(285)
(Loss) income before income taxes	(2,334)	129
Income tax benefit (expense)	856	(88)
Net (loss) income	$ (1,478)	$ 41
Net (loss) income per share:
Basic	$ (0.07)	$ 0
Diluted	$ (0.07)	$ 0
Weighted average shares outstanding:
Basic	22,680,562	22,548,538
Diluted	22,680,562	23,039,256

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Cash Flows [Abstract]
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	$ (1,442)	$ 337
INVESTING ACTIVITIES
Purchase of medical equipment and property	(1,015)	(3,274)
Proceeds from sale of medical equipment and property	1,525	884
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	510	(2,390)
FINANCING ACTIVITIES
Principal payments on revolving credit facility, term loans and capital lease obligations	(6,413)	(15,369)
Cash proceeds from revolving credit facility	4,099	17,081
Debt issuance costs	(25)
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans	(20)	(33)
Cash proceeds from stock plans	87	125
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(2,272)	1,804
Net change in cash and cash equivalents	(3,204)	(249)
Cash and cash equivalents, beginning of period	3,398	818
Cash and cash equivalents, end of period	$ 194	$ 569

Basis of Presentation, Nature o

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies The terms “InfuSystem”, “the Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Medical Equipment

Medical Equipment	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Medical Equipment	2. Medical Equipment Medical equipment is comprised of the following (in thousands): March 31, December 31, 2017 2016 Medical Equipment held for sale or rental $ 1,371 $ 1,642 Medical Equipment in rental service 59,049 59,034 Medical Equipment in rental service - pump reserve (611 ) (551 ) Accumulated depreciation (31,542 ) (30,447 ) Medical Equipment in rental service - net 26,896 28,036 Total $ 28,267 $ 29,678 Depreciation expense for medical equipment for the three months ended March 31, 2017 was $1.6 million, compared to $1.5 million for the same prior year period, which was recorded in cost of revenues – pump depreciation and disposals, for each period.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment Property and equipment is comprised of the following (in thousands): March 31, 2017 December 31, 2016 Gross Accumulated Total Gross Accumulated Total Furniture, fixtures, and equipment $ 3,818 $ (3,116 ) $ 702 $ 3,809 $ (3,071 ) $ 738 Automobiles 118 (75 ) 43 129 (83 ) 46 Leasehold improvements 2,177 (1,008 ) 1,169 2,177 (964 ) 1,213 Total $ 6,113 $ (4,199 ) $ 1,914 $ 6,115 $ (4,118 ) $ 1,997 Depreciation expense for property and equipment for the three months ended March 31, 2017 and 2016 was $0.1 million. This expense was recorded in general and administrative expenses.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets The carrying amount and accumulated amortization of intangible assets is comprised of the following (in thousands): March 31, 2017 December 31, 2016 Gross Accumulated Net Gross Accumulated Net Nonamortizable intangible assets: Trade names $ 2,000 $ — $ 2,000 $ 2,000 $ — $ 2,000 Amortizable intangible assets: Trade names 23 23 — 23 23 — Physician and customer relationships 36,534 20,020 16,514 36,534 19,427 17,107 Non-competition 1,136 1,099 37 1,136 1,064 72 Software 13,546 2,464 11,082 13,745 1,685 12,060 Total nonamortizable and amortizable intangible assets $ 53,239 $ 23,606 $ 29,633 $ 53,438 $ 22,199 $ 31,239 Amortization expense for the three months ended March 31, 2017 was $1.4 million compared to $0.9 million for the three months ended March 31, 2016. Expected annual amortization expense for intangible assets recorded as of March 31, 2017 is as follows (in thousands): 4/1- 12/31/2017 2018 2019 2020 2021 2022 and Amortization expense $ 4,152 $ 5,202 $ 4,769 $ 4,323 $ 3,951 $ 5,236

Debt

Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt	5. Debt On March 23, 2015, the Company and its direct and indirect subsidiaries (the “Borrowers”) entered into a credit agreement (the “Chase Credit Agreement”) with JPMorgan Chase Bank, N.A., as lender (the “Lender”). The Chase Credit Agreement consists of a $27.0 million Term Loan A, up to an $8.0 million Term Loan B and a $10.0 million revolving credit facility (the “Revolver”), all of which mature on March 23, 2020, collectively (the “Credit Facility”). The Borrowers drew $27.0 million under the Term Loan A to repay and terminate the previously existing Credit Facility under the credit agreement dated November 30, 2012, as amended, by and among the Company, its direct and indirect subsidiaries, Wells Fargo Bank, National Association, as administrative agent, and certain lenders party thereto (the “WF Facility”). Term Loan B was unfunded at closing and beginning on April 20, 2015, the closing date of the acquisition of the assets of Ciscura, the Borrowers drew $8.0 million on Term Loan B, in several installments, in accordance with the requirements of the asset purchase agreement governing the acquisition to fund the acquisition and associated expenses. The remaining available amount on Term Loan B expired on March 23, 2016. On December 5, 2016, the Company entered into a First Amendment to the Chase Credit Agreement to waive certain events of default then existing thereunder, as well as to make certain amendments to the Credit Facility, including but not limited to: (i) restructuring of the Credit Facility that effectively consolidated Term Loan A and Term Loan B into a new single term loan (the “Term Loan”) resulting in a new total drawn amount of $32 million under the Term Loan with the approximately $5 million excess over the current aggregate drawn amounts under Term Loan A and Term Loan B to be available to reduce the Company’s drawings under the revolving credit line under the Credit Facility; (ii) extending the maturity date of the Term Loan and the revolving credit line to December 5, 2021; (iii) setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity; and (iv) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018. On March 22, 2017, the Company entered into a Second Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to: (i) amending the definition of “Fixed Charges” to increase the Company’s ability to prepay its indebtedness under the Credit Facility without negatively impacting its financial covenants; and (ii) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019. As of March 31, 2017, the Company breached a financial covenant under its Credit Facility, which resulted in an event of default under the Credit Facility. Specifically, the Company was not in compliance with the leverage ratio covenant under the Credit Facility. The required maximum leverage ratio under the Credit Facility as of March 31, 2017 was 2.75 compared to an actual ratio of 2.96. The Company subsequently received a waiver from this breach from the Lender on May 10, 2017, which provided a limited, specific and one-time waiver from this breach but did not otherwise modify the terms of the Credit Facility. No fee was paid to the Lender in connection with this waiver. Based on the Company’s anticipated operating results, the Company currently expects that it will need to obtain additional amendments to the financial covenants under the Credit Facility to achieve compliance for future periods. As a result, the Company is currently in discussions with the Lender to obtain a third amendment to the Chase Credit Agreement to amend the Credit Facility to, among other things, modify the covenants under the Credit Facility. However, there can be no assurance that the Company will be able to obtain such an amendment or remain in compliance with the covenants under the Credit Facility in the future. If the Company is not able to obtain an acceptable amendment, the Company will need to consider available options and remedies, which may include seeking additional financing to repay its outstanding indebtedness and to continue to fund its operations and its future cash needs. To the extent sought, there can be no assurance that the Company will be able to secure such financing on terms acceptable to it, or at all. The Company’s failure to secure financing when required, could have a material adverse effect on its solvency and its ability to continue as a going concern. In addition, the amount of cash generated from its operations will be dependent upon factors such as the successful execution of its business plan and general economic conditions. As a result of the default, the Company has classified the entire amount of outstanding debt under the Credit Facility as a current liability in its balance sheet as of March 31, 2017, until such time as an amendment is in place. To secure repayment of the obligations of the Borrowers, each Borrower has granted to the Lender, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers. In addition, the Company has pledged the shares of InfuSystem Holdings USA, Inc. (“Holdings USA”) and Holdings USA has pledged the shares of each of InfuSystem, Inc. and First Biomedical, Inc. and the equity interests of IFC, LLC to the Lender, for the benefit of the secured parties, to further secure the obligations under the Chase Credit Agreement. The availability under the Revolver is based upon the Borrower’s eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): March 31, December 31, Revolver: Gross Availability $ 10,000 $ 10,000 Outstanding Draws (1,666 ) — Letter of Credit — — Landlord Reserves (45 ) (45 ) Availability on Revolver $ 8,289 $ 9,955 The Company had approximate future maturities of loans as of March 31, 2017 as follows (in thousands): 2017 2018 2019 2020 2021 Total Term Loan $ 28,832 $ — $ — $ — $ — $ 28,832 Unamortized value of the debt issuance costs (a) (129 ) — — — — (129 ) Revolver 1,666 — — — — 1,666 Total $ 30,369 $ — $ — $ — $ — $ 30,369 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU No. 2015-03. The following is a breakdown of the Company’s current and long-term debt as follows (in thousands): March 31, 2017 Current Long-Term Long-Term Total Term Loan $ 28,832 $ — $ 28,832 Unamortized value of the debt issuance costs (a) $ (129 ) $ — (129 ) Revolver 1,666 — 1,666 Total $ 30,369 $ — $ 30,369 December 31, 2016 Current Long-Term Long-Term Total Term Loans $ 5,336 $ 26,664 $ 32,000 Unamortized value of the debt issuance costs (a) $ (22 ) $ (87 ) (109 ) Revolver — — — Total $ 5,314 $ 26,577 $ 31,891 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU No. 2015-03.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes During the three months ended March 31, 2017, the Company recorded an income tax benefit of $0.9 million. The Company recorded income tax expense of $0.1 million for the same prior year period. In computing its income tax provision, the Company estimates its effective tax rate for the full year and applies that rate to income earned through the reporting period. The Company’s effective income tax rate for the three months ended March 31, 2017 was 36.7% compared to 68.2% for the same prior year period.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	7. Commitments, Contingencies and Litigation From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective. As a result of the restatement of the Company’s consolidated financial statements as of December 31, 2015 and the first and second quarters of 2016, the Company is currently involved in a class-action lawsuit filed by shareholders. On November 8, 2016, a purported shareholder of the Company filed a putative class-action lawsuit in the U.S. District Court for the Central District of California (the “Court”) (Case No. 2:16-cv-08295-ODW) The Company believes that the allegations against it and its officers are without merit and intends to vigorously defend against the claims asserted. The ultimate resolution of this matter cannot be predicted, however, and it is not possible at this time for the Company to estimate any probable loss or range of losses because of the preliminary nature of the matter.

(Loss) Earnings Per Share

(Loss) Earnings Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
(Loss) Earnings Per Share	8. (Loss) Earnings Per Share Basic (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period. Diluted (loss) income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations: Three Months Ended March 31 2017 2016 Numerator: Net (loss) income (in thousands) $ (1,478 ) $ 41 Denominator: Weighted average common shares outstanding: Basic 22,680,562 22,548,538 Dilutive effect of non-vested 0 490,718 Diluted 22,680,562 23,039,256 Net (loss) income per share: Basic $ (0.07 ) $ 0.00 Diluted $ (0.07 ) $ 0.00 For the three months ended March 31, 2017, 0.6 million of stock options were not included in the calculation because they would have an anti-dilutive effect. For the three months ended March 31, 2016, 0.1 million of stock options were not included in the calculation because they would have an anti-dilutive effect.

Leases

Leases	3 Months Ended
	Mar. 31, 2017
Leases [Abstract]
Leases	9. Leases The Company leases office space, service facility centers and equipment under non-cancelable Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable Capital Operating Total 2017 $ 2,273 $ 718 $ 2,991 2018 1,864 831 2,695 2019 608 562 1,170 2020 312 178 490 2021 10 181 191 Thereafter 0 938 938 Total require payments $ 5,067 $ 3,408 $ 8,475 Less amounts representing interest (3.1% to 10.5%) (230 ) Present value of minimum lease payments 4,837 Less current maturities (2,715 ) Long-term capital lease liability $ 2,122 At March 31, 2017 and December 31, 2016, pump assets obtained under capital leases, had a cost of approximately $14.0 million and $13.9 million, respectively, and accumulated depreciation of $4.4 million and $3.9 million, respectively. The Company had minimum future operating lease commitments, mainly related to its leased facilities. Related rental expense for facilities and other equipment from third parties under operating leases for the three months ended March 31, 2017 and 2016 was $0.2 million.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events The Company has evaluated subsequent events through the date of issuance for the unaudited condensed consolidated financial statements.

Recent Accounting Pronouncement

Recent Accounting Pronouncements and Developments	3 Months Ended
	Mar. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	11. Recent Accounting Pronouncements and Developments On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, 2014-09”), 2014-09 No. 2015-14, 2014-09 2014-09 2014-09 In February 2016, the FASB issued ASU No. 2016-02, 2016-02”). 2016-02, right-of-use 2016-02 2016-02 In March 2016, the FASB issued ASU No. 2016-09, “Compensation— Stock Compensation (Topic 718)” (“ASU 2016-09”). The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee’s shares than it can under current guidance for tax withholding purposes providing for withholding at the employee’s maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016. Effective January 1, 2017, the Company adopted the accounting guidance contained within ASU 2016-09. Thus, the Company recorded a $0.2 million deferred tax asset and a $0.2 million increase to retained earnings on January 1, 2017 to recognize the Company’s excess tax benefits that existed as of December 31, 2016 (modified retrospective application). In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses” (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. ASU 2016-13 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-13. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations, cash flows and/or disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods. ASU 2016-15 requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the adoption of this new standard will have a material impact on the Company’s financial position, results of operations or statements of cash flows upon adoption. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. The Company has chosen to apply this guidance prospectively, thus prior periods were not retrospectively adjusted. The adoption of this guidance resulted in the balance sheet reclassification of $2.7 million of current deferred tax assets to noncurrent.

Recent Accounting Pronounceme17

Recent Accounting Pronouncements and Developments (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, 2014-09”), 2014-09 No. 2015-14, 2014-09 2014-09 2014-09 In February 2016, the FASB issued ASU No. 2016-02, 2016-02”). 2016-02, right-of-use 2016-02 2016-02 In March 2016, the FASB issued ASU No. 2016-09, “Compensation— Stock Compensation (Topic 718)” (“ASU 2016-09”). The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee’s shares than it can under current guidance for tax withholding purposes providing for withholding at the employee’s maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016. Effective January 1, 2017, the Company adopted the accounting guidance contained within ASU 2016-09. Thus, the Company recorded a $0.2 million deferred tax asset and a $0.2 million increase to retained earnings on January 1, 2017 to recognize the Company’s excess tax benefits that existed as of December 31, 2016 (modified retrospective application). In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses” (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. ASU 2016-13 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-13. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations, cash flows and/or disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods. ASU 2016-15 requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the adoption of this new standard will have a material impact on the Company’s financial position, results of operations or statements of cash flows upon adoption. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. The Company has chosen to apply this guidance prospectively, thus prior periods were not retrospectively adjusted. The adoption of this guidance resulted in the balance sheet reclassification of $2.7 million of current deferred tax assets to noncurrent.

Medical Equipment (Tables)

Medical Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
Summary of Medical Equipment	Medical equipment is comprised of the following (in thousands): March 31, December 31, 2017 2016 Medical Equipment held for sale or rental $ 1,371 $ 1,642 Medical Equipment in rental service 59,049 59,034 Medical Equipment in rental service - pump reserve (611 ) (551 ) Accumulated depreciation (31,542 ) (30,447 ) Medical Equipment in rental service - net 26,896 28,036 Total $ 28,267 $ 29,678

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment is comprised of the following (in thousands): March 31, 2017 December 31, 2016 Gross Accumulated Total Gross Accumulated Total Furniture, fixtures, and equipment $ 3,818 $ (3,116 ) $ 702 $ 3,809 $ (3,071 ) $ 738 Automobiles 118 (75 ) 43 129 (83 ) 46 Leasehold improvements 2,177 (1,008 ) 1,169 2,177 (964 ) 1,213 Total $ 6,113 $ (4,199 ) $ 1,914 $ 6,115 $ (4,118 ) $ 1,997

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets	The carrying amount and accumulated amortization of intangible assets is comprised of the following (in thousands): March 31, 2017 December 31, 2016 Gross Accumulated Net Gross Accumulated Net Nonamortizable intangible assets: Trade names $ 2,000 $ — $ 2,000 $ 2,000 $ — $ 2,000 Amortizable intangible assets: Trade names 23 23 — 23 23 — Physician and customer relationships 36,534 20,020 16,514 36,534 19,427 17,107 Non-competition 1,136 1,099 37 1,136 1,064 72 Software 13,546 2,464 11,082 13,745 1,685 12,060 Total nonamortizable and amortizable intangible assets $ 53,239 $ 23,606 $ 29,633 $ 53,438 $ 22,199 $ 31,239
Schedule of Expected Annual Amortization Expense for Intangible Assets	Expected annual amortization expense for intangible assets recorded as of March 31, 2017 is as follows (in thousands): 4/1- 12/31/2017 2018 2019 2020 2021 2022 and Amortization expense $ 4,152 $ 5,202 $ 4,769 $ 4,323 $ 3,951 $ 5,236

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Summary of Revolver Based upon Borrower's Eligible Accounts Receivable and Inventory	The availability under the Revolver is based upon the Borrower’s eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): March 31, December 31, Revolver: Gross Availability $ 10,000 $ 10,000 Outstanding Draws (1,666 ) — Letter of Credit — — Landlord Reserves (45 ) (45 ) Availability on Revolver $ 8,289 $ 9,955
Summary of Future Maturities of Loans	The Company had approximate future maturities of loans as of March 31, 2017 as follows (in thousands): 2017 2018 2019 2020 2021 Total Term Loan $ 28,832 $ — $ — $ — $ — $ 28,832 Unamortized value of the debt issuance costs (a) (129 ) — — — — (129 ) Revolver 1,666 — — — — 1,666 Total $ 30,369 $ — $ — $ — $ — $ 30,369 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU No. 2015-03.
Summary of Company's Current and Long-Term Debt	The following is a breakdown of the Company’s current and long-term debt as follows (in thousands): March 31, 2017 Current Long-Term Long-Term Total Term Loan $ 28,832 $ — $ 28,832 Unamortized value of the debt issuance costs (a) $ (129 ) $ — (129 ) Revolver 1,666 — 1,666 Total $ 30,369 $ — $ 30,369 December 31, 2016 Current Long-Term Long-Term Total Term Loans $ 5,336 $ 26,664 $ 32,000 Unamortized value of the debt issuance costs (a) $ (22 ) $ (87 ) (109 ) Revolver — — — Total $ 5,314 $ 26,577 $ 31,891 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU No. 2015-03.

(Loss) Earnings Per Share (Tabl

(Loss) Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Numerators and Denominators of Basic and Diluted Income per Share	The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations: Three Months Ended March 31 2017 2016 Numerator: Net (loss) income (in thousands) $ (1,478 ) $ 41 Denominator: Weighted average common shares outstanding: Basic 22,680,562 22,548,538 Dilutive effect of non-vested 0 490,718 Diluted 22,680,562 23,039,256 Net (loss) income per share: Basic $ (0.07 ) $ 0.00 Diluted $ (0.07 ) $ 0.00

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2017
Leases [Abstract]
Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases	Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable Capital Operating Total 2017 $ 2,273 $ 718 $ 2,991 2018 1,864 831 2,695 2019 608 562 1,170 2020 312 178 490 2021 10 181 191 Thereafter 0 938 938 Total require payments $ 5,067 $ 3,408 $ 8,475 Less amounts representing interest (3.1% to 10.5%) (230 ) Present value of minimum lease payments 4,837 Less current maturities (2,715 ) Long-term capital lease liability $ 2,122

Medical Equipment - Summary of

Medical Equipment - Summary of Medical Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Medical Equipment And Property [Abstract]
Medical equipment held for sale or rental	$ 1,371	$ 1,642
Medical Equipment in rental service	59,049	59,034
Medical Equipment in rental service - pump reserve	(611)	(551)
Accumulated depreciation	(31,542)	(30,447)
Medical Equipment in rental service - net	26,896	28,036
Total	$ 28,267	$ 29,678

Medical Equipment - Additional

Medical Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense for medical equipment	$ 1.6	$ 1.5

Property and Equipment - Proper

Property and Equipment - Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Gross Assets	$ 6,113	$ 6,115
Accumulated Depreciation	(4,199)	(4,118)
Total	1,914	1,997
Furniture, Fixtures, and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross Assets	3,818	3,809
Accumulated Depreciation	(3,116)	(3,071)
Total	702	738
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Gross Assets	118	129
Accumulated Depreciation	(75)	(83)
Total	43	46
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross Assets	2,177	2,177
Accumulated Depreciation	(1,008)	(964)
Total	$ 1,169	$ 1,213

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Total depreciation expense recorded	$ 0.1	$ 0.1

Intangible Assets - Summary of

Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Total nonamortizable and amortizable intangible assets, Gross Assets	$ 53,239	$ 53,438
Total nonamortizable and amortizable intangible assets, Accumulated Amortization	23,606	22,199
Total nonamortizable and amortizable intangible assets, Net	29,633	31,239
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	23	23
Amortizable intangible assets, Accumulated Amortization	23	23
Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	36,534	36,534
Amortizable intangible assets, Accumulated Amortization	20,020	19,427
Amortizable intangible assets, Net	16,514	17,107
Non-Competition Agreements [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	1,136	1,136
Amortizable intangible assets, Accumulated Amortization	1,099	1,064
Amortizable intangible assets, Net	37	72
Software [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	13,546	13,745
Amortizable intangible assets, Accumulated Amortization	2,464	1,685
Amortizable intangible assets, Net	11,082	12,060
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Nonamortizable intangible assets	$ 2,000	$ 2,000

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,411	$ 912

Intangible Assets - Schedule of

Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense, 2017	$ 4,152
Amortization expense, 2018	5,202
Amortization expense, 2019	4,769
Amortization expense, 2020	4,323
Amortization expense, 2021	3,951
Amortization expense, 2022 and thereafter	$ 5,236

Debt - Additional Information (

Debt - Additional Information (Detail)	Mar. 22, 2017	Dec. 05, 2016USD ($)	Mar. 31, 2017USD ($)	Mar. 23, 2015USD ($)
Line of Credit Facility [Line Items]
Actual leverage ratio			2.96
First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amendment to Credit Agreement, description			Amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018.
Second Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amendment to Credit Agreement, description	Amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019.
JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Credit facility, maturity date			Mar. 23, 2020
Term Loan A [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility				$ 27,000,000
Term Loan A [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				27,000,000
Term Loan B [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility				8,000,000
Term Loan B [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				8,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility			$ 1,666,000
Revolving Credit Facility [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				$ 10,000,000
Term Loan [Member]
Line of Credit Facility [Line Items]
Frequency of period payment			Setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity
Term Loan [Member] | First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility		$ 32,000,000
Additional available balance		5,000,000
Debt instrument period payment, principal amount		$ 1,300,000
Maximum [Member] | First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2017		2.75%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2017 but prior to March 31, 2018		2.50%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018		2.25%
Maximum [Member] | Second Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2018	2.75%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018 but prior to March 31, 2019	2.50%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2019	2.25%

Debt - Summary of Revolver Base

Debt - Summary of Revolver Based upon Borrower's Eligible Accounts Receivable and Inventory (Detail) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Gross Availability	$ 10,000	$ 10,000
Outstanding Draws	(1,666)
Letter of Credit	0	0
Landlord Reserves	(45)	(45)
Availability on Revolver	$ 8,289	$ 9,955

Debt - Summary of Future Maturi

Debt - Summary of Future Maturities of Loans (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
2,017	$ 30,369
Total	30,369	$ 31,891
Unamortized value of the debt issuance costs, 2017	(129)
Unamortized value of the debt issuance costs, 2018	0
Unamortized value of the debt issuance costs, 2019	0
Unamortized value of the debt issuance costs, 2020	0
Unamortized value of the debt issuance costs, 2021	0
Unamortized value of the debt issuance costs, Total	(129)	(109)
Term Loan [Member]
Line of Credit Facility [Line Items]
2,017	28,832
Total	28,832	$ 32,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
2,017	1,666
Total	$ 1,666

Debt - Summary of Company's Cur

Debt - Summary of Company's Current and Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Current portion of long-term debt	$ 30,369	$ 5,314
Long-Term Debt		26,577
Total	30,369	31,891
Unamortized value of the debt issuance costs, Current Portion of Long-Term Debt	(129)	(22)
Unamortized value of the debt issuance costs, Long-Term Debt		(87)
Unamortized value of the debt issuance costs, Total	(129)	(109)
Term Loan [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	28,832	5,336
Long-Term Debt		26,664
Total	28,832	$ 32,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	1,666
Total	$ 1,666

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (856)	$ 88
Effective income tax rate	36.70%	68.20%

Commitments, Contingencies an36

Commitments, Contingencies and Litigation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017
Pending Litigation [Member] | The Complaint [Member]
Loss Contingencies [Line Items]
Lawsuit Filing Date	Nov. 8, 2016

(Loss) Earnings Per Share - Num

(Loss) Earnings Per Share - Numerators and Denominators of Basic and Diluted Income per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net (loss) income	$ (1,478)	$ 41
Weighted average common shares outstanding:
Basic	22,680,562	22,548,538
Dilutive effect of non-vested awards	0	490,718
Diluted	22,680,562	23,039,256
Net (loss) income per share:
Basic	$ (0.07)	$ 0
Diluted	$ (0.07)	$ 0

(Loss) Earnings Per Share - Add

(Loss) Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stock Options [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares with anti-dilutive effect	0.6	0.1

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Leases [Line Items]
Pump equipment	$ 14		$ 13.9
Accumulated depreciation related to leased assets	4.4		$ 3.9
Operating lease rental expenses	$ 0.2	$ 0.2
Capital Leases [Member]
Leases [Line Items]
Weighted average interest rate under capital leases	4.60%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Leases [Abstract]
Capital leases, 2017	$ 2,273
Capital leases, 2018	1,864
Capital leases, 2019	608
Capital leases, 2020	312
Capital leases, 2021	10
Capital leases, Thereafter	0
Total capital leases require payments	5,067
Less amounts representing interest (3.1% to 10.5%)	(230)
Present value of minimum lease payments	4,837
Present value of minimum lease payments	4,837
Less current maturities	(2,715)	$ (2,938)
Long-term capital lease liability	2,122	$ 2,573
Operating leases, 2017	718
Operating leases, 2018	831
Operating leases, 2019	562
Operating leases, 2020	178
Operating leases, 2021	181
Operating leases, Thereafter	938
Total operating leases require payments	3,408
Capital and operating leases, 2017	2,991
Capital and operating leases, 2018	2,695
Capital and operating leases, 2019	1,170
Capital and operating leases, 2020	490
Capital and operating leases, 2021	191
Capital and operating leases, Thereafter	938
Total Capital and operating leases require payments	$ 8,475

Leases - Schedule of Future M41

Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Parenthetical) (Detail)	Mar. 31, 2017
Minimum [Member]
Capital Leases And Operating Leases [Line Items]
Capital lease interest rate	3.10%
Maximum [Member]
Capital Leases And Operating Leases [Line Items]
Capital lease interest rate	10.50%

Recent Accounting Pronounceme42

Recent Accounting Pronouncements and Developments - Additional Information (Detail) - Adjustments for New Accounting Principle, Early Adoption [Member] - USD ($) $ in Millions	Jan. 01, 2017	Mar. 31, 2017
Retained Deficit [Member] | ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement	$ 0.2
Deferred Tax Asset [Member] | ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement	$ 0.2
Deferred Tax Asset Non Current [Member] | ASU 2015-17 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement		$ 2.7